Analysts Set Organon & Co. (NYSE:OGN) Price Target at $11.40

Organon & Co. (NYSE:OGN) has been assigned a consensus rating of “Reduce” from the seven brokerages that are currently covering the firm, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell rating and five have issued a hold rating on the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $11.40.

Several research analysts recently commented on the company. Piper Sandler upgraded Organon & Co. from an “underweight” rating to a “neutral” rating and lifted their price target for the stock from $5.00 to $14.00 in a research report on Tuesday, April 28th. Barclays lifted their price target on Organon & Co. from $7.50 to $8.00 and gave the stock an “underweight” rating in a research report on Tuesday, February 24th. Zacks Research upgraded Organon & Co. from a “strong sell” rating to a “hold” rating in a research report on Tuesday, April 14th. Weiss Ratings raised shares of Organon & Co. from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Friday, May 15th. Finally, Wall Street Zen downgraded shares of Organon & Co. from a “buy” rating to a “hold” rating in a research note on Saturday, January 31st.

Insider Transactions at Organon & Co.

In other news, SVP Lynette Holzbaur acquired 26,448 shares of the firm’s stock in a transaction on Wednesday, May 6th. The stock was acquired at an average price of $13.35 per share, with a total value of $353,080.80. Following the completion of the purchase, the senior vice president directly owned 52,851 shares in the company, valued at approximately $705,560.85. This trade represents a 100.17% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 1.62% of the stock is currently owned by insiders.

Institutional Trading of Organon & Co.

Several institutional investors have recently added to or reduced their stakes in OGN. AQR Capital Management LLC lifted its stake in Organon & Co. by 105.2% in the fourth quarter. AQR Capital Management LLC now owns 8,570,958 shares of the company’s stock worth $61,282,000 after purchasing an additional 4,394,814 shares during the last quarter. Vanguard Group Inc. lifted its stake in Organon & Co. by 11.3% in the third quarter. Vanguard Group Inc. now owns 35,928,403 shares of the company’s stock worth $383,715,000 after purchasing an additional 3,650,860 shares during the last quarter. UBS Group AG raised its stake in shares of Organon & Co. by 55.2% during the fourth quarter. UBS Group AG now owns 4,295,002 shares of the company’s stock valued at $30,795,000 after acquiring an additional 1,527,492 shares in the last quarter. First Trust Advisors LP raised its stake in shares of Organon & Co. by 78.1% during the first quarter. First Trust Advisors LP now owns 3,227,320 shares of the company’s stock valued at $19,332,000 after acquiring an additional 1,415,239 shares in the last quarter. Finally, Private Management Group Inc. raised its stake in shares of Organon & Co. by 38.3% during the fourth quarter. Private Management Group Inc. now owns 4,347,073 shares of the company’s stock valued at $31,169,000 after acquiring an additional 1,204,979 shares in the last quarter. Institutional investors own 77.43% of the company’s stock.

Organon & Co. Trading Up 0.1%

OGN opened at $13.44 on Friday. The firm has a market cap of $3.53 billion, a P/E ratio of 14.45, a P/E/G ratio of 1.24 and a beta of 1.57. Organon & Co. has a 12 month low of $5.69 and a 12 month high of $13.48. The company has a current ratio of 1.97, a quick ratio of 1.42 and a debt-to-equity ratio of 9.47. The stock has a 50-day moving average of $9.43 and a 200 day moving average of $8.24.

Organon & Co. (NYSE:OGN) last released its quarterly earnings results on Thursday, April 30th. The company reported $0.71 EPS for the quarter, missing the consensus estimate of $0.83 by ($0.12). The company had revenue of $1.46 billion during the quarter, compared to analysts’ expectations of $1.49 billion. Organon & Co. had a return on equity of 99.95% and a net margin of 3.99%.The company’s revenue was down 3.5% on a year-over-year basis. During the same quarter in the prior year, the business posted $1.02 EPS. As a group, research analysts forecast that Organon & Co. will post 3.23 EPS for the current year.

Organon & Co. Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, June 11th. Shareholders of record on Monday, May 11th will be paid a $0.02 dividend. The ex-dividend date of this dividend is Monday, May 11th. This represents a $0.08 annualized dividend and a yield of 0.6%. Organon & Co.’s dividend payout ratio (DPR) is presently 8.60%.

About Organon & Co.

Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.

In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.